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829-5 Clinical Effects of Spinal Cord Stimulation in Patients 
With Refractory Angina Pectoris: Results From a 
Prospective Italian Registry 
Gaetano A. Lanza. Francesco DI Pede, Guerrino Zuin, Massimo Romanb, Dine Flap&i, 
Antonio Circa, Paola Cardano, Fulvio Bellocci, Ottavio Alfieri, Massimo Santini, Attilio 
Masen, for the Prospective Italian Registry of SCS for Refractory Angina, Roma, Italy 
Background. The treatment of patients with angma pectoris refractory to medical therapy 
and unsuitable for revascularization procedures is a challenging problem in the modern 
cardiology but it is not well standardized yet. Previous large retrospective studies and 
small prospective studies suggested beneficial effects of spinal cord stimutation (SCS) in 
these patients. 
Method. We organized a Prospective Multicenter Italian Registry of SCS to evaluate the 
short and long term clinical outcome of patients undergoing SCS device implantation 
because of severe refractmy angina pectoris and the clinical effects of this form of ther- 
apy. Patients were followed-up with periodic medical visits in out-patient clinics. 
Results. Overall, 104 patients were enrolled in the Registry (70 men, age 67.&17 years), 
most of whom (83%) had 3.vessel coronary artery disease. Average follow-up was 
13.2+7.9 months, ranging from 6 to 24 months. Overall, 17 patients (16.8%) died during 
the follow-up period, 8 (7.9%) of whom of cardtac death. Among clinical variables, only 
age was found to be significantly associated both with total mortality (p=O.O4) and car- 
diac mortality (P=O.O2) on Cox regression analysis. At the last follow-up, a significant 
improvement of angina1 symptoms (>50% reduction of weekly angina1 episodes, com- 
pared to baseline) was reported by 73.0% of patients, and the Canadian Cardiovacular 
Society class of angina was improved by ~1 class in 80.5% and by x2 classes in 
42.3% of patients. A relevant reduction in the rate of hospital admission and days spent 
in the hospital because of angina (pcO.0001 for both) was also observed. No life-threat- 
ening or clinically serious events were observed as related to the SCS treatment. 
Conclusions. Our prospective data show that SCS can be performed safely and is asso- 
ciated with a sustained improvement of angina1 symptoms in a relevant number of 
patients with refractory stable angina pectoris. suggesting that it should be seriously 
taken into account for the treatment of these patients. 
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829-6 Excess of Mortality in Patients With Endothelial 
Dysfunction 
Tatsuaki Murakami. Kazuo Ohsato, Fukui Cardiovascular Center, Fukul, Japan 
Background: Although endothelial dysfunction (ED) is thought to contribute to athero- 
thrombogenic processes, the relationship between ED and mortality, an extreme medical 
endpoint, remains unknown. This study investigated whether ED has prognostic impacts. 
Methods: ED was graded by noninvasively ultrasonic measured reactive changes in 
lumen diameter of right brachial artery following transient occlusion for 5 minutes (FMD; 
flow-mediated endothelium-dependent vasodilation) in consecutive 518 ambulatory 
patients with suspected coronary altery disease. The enrolled patients were categorized 
into 3 groups according to the values of FMD, and their fatal events were prospectively 
followed-up for no less than 24 months. Results: For a mean follow-up period of 45 
months with 100% follow-up, the patients with severe endothelial dysfunction (FMD<4%; 
Group-L, n=174) more frequently resulted in cardiovascular death than those in Group-M 
with mild endothelial dysfunction (4%<FMDc8%, n=l71) and Group-H with preserved 
endothelial function (FMD 8% or more, n=l73)[by Kaplan-Meier analysis] and more fre- 
quently resulted in non-cardiovascular death. Cox proportional hazard model analyses 
showed that severe endothelial dysfunction was significantly associated with future car- 
dlovascular and non-cardiovascular death. Conclusion: These results suggest noninva- 
sive assessment of endothelial dysfunction predicts future fatal events and stratify 
patients who are at high risk or low risk of mortality 
Group-L Group-M Group-H Odds Ratio P-Value 
Cardiovascular Death 8 (4.6%) 1 (0.6%) 1 (0.6%) 9.85 0.035 
Non-Cardiovascular Death 7 (4.0%) 3 (1.7%) 1 (0.6%) 7.43 0.049 
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836-l Lack of Benefit From Cytokine Mobilized Stem Cell 
Therapy for Acute Myocardial Infarction in Nonhuman 
Primates 
Andrew E. Arai, Farooq Sheikh, Kwabena 0. Agyeman, Robert Hoyt, Vandana Sachdev. 
Xu-Xi Yu, Hong San, Mark Metzger, Cynthia Dunbar, Donald Orlic, National Institutes of 
Health, Bethesda, MD 
Background: Mobilization of stem cells with stem cell factor (SCF) and granulocyte-col- 
any-stimulating factor (G-CSF) resulted in myocardial regeneration, improved ventricular 
function, and Improved mortality in mice with acute myocardial Infarction (Ml). We 
hypothesized that either single therapy with G-CSF or combination therapy with SCFIG- 
CSF would result in myocardial regeneration m monkeys after MI. Methods: Rhesus 
monkeys were treated with G-CSF (n=7) or SCFIG-CSF (n=7) subcutaneously on 8 con- 
secutive days starting 4 days prior and continuing 3 days after Ml was induced by a 2- 
hour occlusion of the LAD. Control animals (n-7) had the same surgery and infarction but 
no cytokine therapy. Stem cell mobilization was confirmed by serial blood tests. Gadolin- 
ium enhanced MRI was performed before, 1 week after, 6 weeks after, and 12 weeks 
after Ml. Results: Circulating primitive CD34+ progenitor cells were highest for the SCF/ 
G-CSF group (71+/-27 cells/uL), intermediate for the G-CSF group (31+/-13 cellsiul). 
and minimal for the control group (2+/-2 cells/uL). Post-MI mortality was 71% in the SCF/ 
G-CSF group vs 14% in the G-CSF group (p=O.lO) and 29% in the control group 
(p=O.28). None of the SCF/G-CSF mortality was attributed to anaphylaris and all deaths 
occurred in the post-MI period. The infarct size averaged 30% of the left ventricle in the 
SCF/G-CSF group (n=2 survivors). 24% in the G-CSF group, and 21% in the control 
group. MRI indices of ventricular volumes and ejection fraction showed unfavorable but 
nonsignificant trends toward worse outcome in both treatment groups compared to con- 
trols. One week post-MI, LV ejection fraction averaged 49% (n=2 survivors), 49%, and 
58% in the SCFIG-CSF. G-CSF. and control groups respectively. Conclusions: The lack 
of favorable treatment trends and the unexpectedly high mortality in the SCFIG-CSF 
group despite excellent primitive cell mobilization raise concerns regarding cyiokine ther- 
apy in the peri-infarct period. Compared with a prior successful study in mice, the current 
protocol used rhesus monkeys, a repeffused Infarct model, and generally smaller infarc- 
tions. High white blood cell counts may have adversely affected reperfusion in the mon- 
keys. 
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836-2 Matrix Metalloproteinase Inhibition Limits Remodeling 
and Regional Systolic Dysfunction but Not Myocyte 
Hypertrophy Following Myocardial Infarction 
Sunil Mankad. J. Thomas Peterson, Robert W. Biederman, Walter E. McGregor, 
Deborah Scalise, James A. Magovern, Xinqiang Han, Carol Stolarski, Brent Anderson, A. 
Martin Gerdes, Nathaniel Reichek. Richard P. Shannon, Allegheny General Hospital, 
Pittsburgh, PA 
Background: Myocardial matrix metalloproteinase (MMP) activity is increased after MI, 
but effects of MMP inhibition (MMPi) on LV systolic function, myocyie hypeltrophy, tumor 
necrosis factor (TNF). and nitric oxide synthase (NOS) are unclear. Methods: 1 day after 
anteroapical MI, sheep were randomized to MMPi (PDl66793-Pfizer, Inc; n=lO) or no 
therapy (Control; n=lO). Magnetic resonance imaging was performed before and 8 
weeks after Ml to quantify changes in LV end-systolic volume index, end-diastolic volume 
index. eiection fraction. LV mass index. and adiacent (within 2 cm of infarct) circumferen- 
tial strain (%S). Myocyle morphometry , Western analyses and immunohistochemistry 
were assessed at E-weeks oost-MI. Results: MMPi limited LV remodelina (see Table. 
‘p<O.Ol vs control), but no differences in adjacent myocyte hypertrophy were seen (cell 
volume: 3.4eO.6 vs 3.5eO.4 x 104um3; cell length: 157216 vs 157i8 urn; and cross-sec- 
tional area: 228+26 vs 227*27 ud ; p=ns for Control vs MMPi for all). MMPi was associ- 
ated with decreased adjacent constitutive NOS and increased adjacent inducible NOS. 
There was a trend towards decreased adjacent TNF with MMPi: 612*75 vs 749*73 den- 
sity units (~~0.2). Conclusion: MMPi attenuated LV remodeling and reduced adjacent 
myocardial systolic dysfunction post-MI. In contrast to renin-angiotensin blockade in this 
model, beneficial effects of MMPi were not associated with reduced adjacent myocyte 
hypertrophy. Effects of MMPi on regulatory cytokines may play a role. 
